Positive clinical-trial results couldn't save the embroiled biotech.
News & Analysis: Mallinckrodt
MNK earnings call for the period ending June 30, 2019.
The drugmaker's decision to suspend efforts to spin off its specialty generics business appears to be rattling investors.
Worrisome information from a major opioid case appears to be weighing on the drug stock.
Another bump in the road for Acthar is weighing on the drugmaker.
These drug developers are all valued at less than four times this year's projected earnings per share.
Tough conditions for these companies left them out of the day's rally.
The company filed a lawsuit to stop a federal decision that could be very bad news for its top drug.
Forty-four states have brought a lawsuit against the industry.
MNK earnings call for the period ending March 31, 2019.